As of May 27, 2025, Ardelyx Inc (ARDX) reports a Gross Margin of 84.85%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Ardelyx Inc's Gross Margin
Over recent years, Ardelyx Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 84.85% |
| 2023-12-31 | 85.70% |
| 2022-12-31 | 92.10% |
| 2021-12-31 | 90.10% |
| 2020-12-31 | 98.02% |
This slight upward trend highlights how Ardelyx Inc manages its operational efficiency and pricing power over time.
Comparing Ardelyx Inc's Gross Margin to Peers
To better understand Ardelyx Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Ardelyx Inc (ARDX) | 84.85% |
| Dyne Therapeutics Inc (DYN) | 7775.20% |
| IVERIC bio Inc (ISEE) | 7775.20% |
| Molecular Templates Inc (MTEM) | 7775.20% |
| Magenta Therapeutics Inc (MGTA) | 7775.20% |
| Kalvista Pharmaceuticals Inc (KALV) | 7775.20% |
Compared to its competitors, Ardelyx Inc's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.